Loading stock data…
UTHR
$572.20-9.02 (-1.55%)
Pre-Market$548.02-24.18 (-4.23%)· Last close May 5
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
United Therapeutics Corporation in the Healthcare sector is trading at $572.20. The stock is currently near its 52-week high of $607.89, remaining 24.9% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why UTHR maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$572.20
Potential Upside
4.5%
Whystock Fair Value$598.12
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$644.62+12.7%
Range$519.00 – $733.00
Fundamentals
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$25.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.57
Beta
Defensive asset. Lower volatility than the S&P 500.
0.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.50%
Volume
Today's trading volume
553,052
Recent News
Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of United Therapeutics (UTHR) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
ImmunityBio to Report Q1 Earnings: What's in the Cards?
IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Assessing United Therapeutics (UTHR) Valuation After A Strong Multi Year Share Price Run
Why United Therapeutics Is On Investors’ Radar United Therapeutics (UTHR) is drawing attention after a period of strong share performance, with the stock showing a 94% total return over the past year and 166% over the past 3 years. At a recent close of US$570.40 and a market cap of about US$25.0b, the company combines sizeable scale with positive annual revenue and net income growth. This is leading some investors to reassess its current valuation. See our latest analysis for United...
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.